- Roche Holding Ag
- 18 November 2025 09:41:33
Source: Sharecast
Phase III results from the lidERA breast cancer study met their primary endpoint, showing a "statistically significant and clinically meaningful" improvement in invasive disease-free survival with giredestrant compared with standard endocrine therapy.
As a result, giredestrant is now the first selective oestrogen receptor degrader or SERD to demonstrate a significant benefit in the so-called adjuvant setting (meaning it is applied after initial cancer treatment).
“Today’s results underscore the potential of giredestrant as a new endocrine therapy of choice for people with early-stage breast cancer, where there is a chance for cure,” said Levi Garraway, Roche's chief medical officer and head of product development.
“Given that ER-positive breast cancer accounts for approximately 70% of cases diagnosed, these findings – together with recent data in the advanced ER-positive setting – suggest that giredestrant has the potential to improve outcomes for many people with this disease.”
Roche shares were up 6.3% at CHF305.20 by 0922 GMT, rising to levels not seen since March.